CN101057859A - 一种解聚海参糖胺聚糖组合物及其制备方法和用途 - Google Patents
一种解聚海参糖胺聚糖组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN101057859A CN101057859A CN 200710017839 CN200710017839A CN101057859A CN 101057859 A CN101057859 A CN 101057859A CN 200710017839 CN200710017839 CN 200710017839 CN 200710017839 A CN200710017839 A CN 200710017839A CN 101057859 A CN101057859 A CN 101057859A
- Authority
- CN
- China
- Prior art keywords
- sea cucumber
- glycosaminoglycan extracted
- depolymerization glycosaminoglycan
- stichopus japonicus
- depolymerization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000251511 Holothuroidea Species 0.000 title claims abstract description 162
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 229920002683 Glycosaminoglycan Polymers 0.000 title claims description 161
- 239000000203 mixture Substances 0.000 title claims description 81
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 52
- 239000005017 polysaccharide Substances 0.000 claims abstract description 52
- 150000004676 glycans Chemical class 0.000 claims abstract description 51
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 23
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 20
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 16
- 208000015294 blood coagulation disease Diseases 0.000 claims abstract description 5
- 230000000593 degrading effect Effects 0.000 claims abstract description 3
- 241000965254 Apostichopus japonicus Species 0.000 claims description 73
- 238000002347 injection Methods 0.000 claims description 45
- 239000007924 injection Substances 0.000 claims description 45
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 17
- 239000003937 drug carrier Substances 0.000 claims description 14
- 241000208340 Araliaceae Species 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 235000008434 ginseng Nutrition 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 238000001556 precipitation Methods 0.000 claims description 10
- 230000023555 blood coagulation Effects 0.000 claims description 9
- 239000012043 crude product Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000008107 starch Substances 0.000 claims description 8
- 235000019698 starch Nutrition 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 108091005658 Basic proteases Proteins 0.000 claims description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- 241000529895 Stercorarius Species 0.000 claims description 3
- 241000960984 Stichopus chloronotus Species 0.000 claims description 3
- 241000887536 Stichopus horrens Species 0.000 claims description 3
- 241000941620 Thelenota ananas Species 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 58
- 239000003814 drug Substances 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 28
- 239000008280 blood Substances 0.000 description 28
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 24
- 241000700159 Rattus Species 0.000 description 24
- 229920000669 heparin Polymers 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 229960002897 heparin Drugs 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 206010008118 cerebral infarction Diseases 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 206010008120 Cerebral ischaemia Diseases 0.000 description 13
- 201000006474 Brain Ischemia Diseases 0.000 description 12
- 239000003146 anticoagulant agent Substances 0.000 description 11
- 230000002490 cerebral effect Effects 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 239000009692 xuesetong Substances 0.000 description 10
- 229940127219 anticoagulant drug Drugs 0.000 description 9
- -1 polysaccharide compound Chemical class 0.000 description 9
- 108010049003 Fibrinogen Proteins 0.000 description 8
- 102000008946 Fibrinogen Human genes 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 229940012952 fibrinogen Drugs 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002429 anti-coagulating effect Effects 0.000 description 6
- 230000010100 anticoagulation Effects 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229960000711 alprostadil Drugs 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000000795 conjunctiva Anatomy 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004411 Antithrombin III Human genes 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 3
- 102000007625 Hirudins Human genes 0.000 description 3
- 108010007267 Hirudins Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229960005348 antithrombin iii Drugs 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229940006607 hirudin Drugs 0.000 description 3
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 206010023683 lagophthalmos Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003188 neurobehavioral effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 101800000263 Acidic protein Proteins 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- GKPYBONTPMSKNX-UHFFFAOYSA-N N1N=NN=C1.[Cl] Chemical compound N1N=NN=C1.[Cl] GKPYBONTPMSKNX-UHFFFAOYSA-N 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- XPYGGHVSFMUHLH-UUSULHAXSA-N falecalcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(O)(C(F)(F)F)C(F)(F)F)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C XPYGGHVSFMUHLH-UUSULHAXSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000002021 Enophthalmos Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 241000941624 Holothuria atra Species 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000035992 Postmortem Changes Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000422846 Sequoiadendron giganteum Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000020992 contracted pupil Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000012716 precipitator Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
样品名称 | Mn(Da) | Mw(Da) | 多分散性 |
解聚海参糖胺聚糖 | 7352 | 10000 | 1.360025 |
组别 | 剂量(mg/kg) | Bederson’s积分值 |
假手术对照组脑缺血模型组血塞通注射液组解聚海参糖胺聚糖大剂量组解聚海参糖胺聚糖中剂量组解聚海参糖胺聚糖小剂量组 | 41.2421 | 09.80±0.428.90±0.57※※8.20±0.42※※▲▲9.30±0.48※9.60±0.70 |
组别 | 剂量(mg/kg) | 脑梗塞体积比率(%) |
假手术对照组脑缺血模型组血塞通注射液组解聚海参糖胺聚糖大剂量组解聚海参糖胺聚糖中剂量组解聚海参糖胺聚糖小剂量组 | 41.2421 | 041.69±6.1625.05±3.96※※19.93±3.86※※25.86±5.34※※44.74±5.53 |
组别 | 剂量(mg/kg) | 脑指数(g/100g) |
假手术对照组脑缺血模型组血塞通注射液组解聚海参糖胺聚糖大剂量组解聚海参糖胺聚糖中剂量组解聚海参糖胺聚糖小剂量组 | 0.6641.2421 | 00.660±0.0320.721±0.0310.714±0.0280.719±0.0350.720±0.020 |
项目 | 正常组 | 模型组 | 阳性组 | 大剂量组 | 中剂量组 | 小剂量组 |
高切变率粘度(mPa·s) | 5.31±0.41 | 6.83±0.56▲▲ | 5.47±0.46※※ | 5.38±0.44 | 5.60±0.46 | 6.20±0.40※※ |
低切变率粘度(mPa·s) | 8.79±0.68 | 12.22±0.86▲▲ | 9.65±0.70** | 9.23±0.67※※ | 9.86±1.32※※ | 11.17±1.11※ |
血浆粘度(mPa·s) | 3.87±0.27 | 4.89±0.37▲▲ | 3.98±0.30※※ | 3.95±0.31※※ | 4.05±0.31※※ | 4.48±0.2※ |
还原粘度(mPa·s) | 10.17±1.40 | 14.32±1.38 | 10.67±1.19※※ | 10.08±0.88○※ | 10.80±1.02※※ | 12.53±1.26 |
血沉(mm/h) | 1.30±0.58 | 1.35±0.78 | 1.60±1.34 | 1.85±1.73 | 1.55±0.99 | 1.35±0.59 |
红细胞压积(%) | 42.75±3.49 | 42.4±1.93 | 43.85±1.17 | 41.86±2.64 | 42.45±1.96 | 41.76±2.83 |
纤维蛋白原(g/l) | 2.25±0.30 | 3.08±0.55▲▲ | 2.26±0.62※※ | 2.04±0.47※※ | 2.17±0.31※※ | 2.30±0.45※※ |
血小板粘附率(%) | 21.95±7.11 | 30.68±5.43▲▲ | 23.10±4.01※※ | 23.15±6.08※※ | 23.21±3.42※※ | 25.75±3.21※※ |
组别 | 剂量(mg/g) | 动物数(只) | 血栓湿重(mg) | 抑制率(%) |
对照组血塞通注射液组解聚海参糖胺聚糖大剂量组解聚海参糖胺聚糖中剂量组解聚海参糖胺聚糖小剂量组 | 41.2421 | 10101010 | 102.70+16.8771.50±11.96※※68.20±14.17※※81.90±15.55※※84.95±12.28※ | 30.3833.6920.2517.28 |
组别 | 动物数 | 微血管血液流速(μm) | 毛细血管网交点数(条) | ||
给药前 | 给药后 | 给药前 | 给药后 | ||
对照组阳性组大剂量组中剂量组小剂量组 | 888108 | 16.65±1.715.4±1.4915.4±1.6415.8±1.3915.9±1.31 | 16.6±1.9618.1±1.41※※18.3±2.1417.4±1.47※17.2±1.46 | 3.78±1.714.0±0.94.0±0.843.75±0.893.88±0.83 | 4.01±0.935.25±0.71※※5.4±1.33※5.13±1.13※4.75±1.04※ |
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100178396A CN100525777C (zh) | 2007-05-14 | 2007-05-14 | 一种解聚海参糖胺聚糖组合物及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100178396A CN100525777C (zh) | 2007-05-14 | 2007-05-14 | 一种解聚海参糖胺聚糖组合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101057859A true CN101057859A (zh) | 2007-10-24 |
CN100525777C CN100525777C (zh) | 2009-08-12 |
Family
ID=38864262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007100178396A Active CN100525777C (zh) | 2007-05-14 | 2007-05-14 | 一种解聚海参糖胺聚糖组合物及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100525777C (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011054174A1 (zh) * | 2009-11-06 | 2011-05-12 | 深圳海王药业有限公司 | 低聚岩藻糖化糖胺聚糖及其制备方法 |
WO2011063595A1 (zh) * | 2009-11-25 | 2011-06-03 | 深圳海王药业有限公司 | 低聚凤梨参糖胺聚糖及其制备方法 |
CN102218076A (zh) * | 2011-04-14 | 2011-10-19 | 易杨华 | 仿刺参多糖及其在制备防治老年痴呆药物或食品中的应用 |
CN102329397A (zh) * | 2011-10-19 | 2012-01-25 | 中国科学院昆明植物研究所 | 一种岩藻糖化糖胺聚糖衍生物及其制备方法 |
CN101451157B (zh) * | 2008-12-25 | 2012-09-05 | 大连海晏堂生物有限公司 | 一种低分子量海参多糖的制备方法 |
CN104147039A (zh) * | 2013-05-13 | 2014-11-19 | 上海开润生物医药有限公司 | 黑海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
CN104263788A (zh) * | 2014-09-25 | 2015-01-07 | 冯群力 | 一种海参多肽的制备方法 |
CN106137896A (zh) * | 2015-04-15 | 2016-11-23 | (株)新韩Eco | 一种利用刺参制备功能性原料的方法 |
CN106349397A (zh) * | 2015-07-23 | 2017-01-25 | 苏州颐华生物医药技术股份有限公司 | 解聚海参糖胺聚糖组合物及其制备方法与应用 |
-
2007
- 2007-05-14 CN CNB2007100178396A patent/CN100525777C/zh active Active
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101451157B (zh) * | 2008-12-25 | 2012-09-05 | 大连海晏堂生物有限公司 | 一种低分子量海参多糖的制备方法 |
CN101735336B (zh) * | 2009-11-06 | 2012-07-18 | 深圳海王药业有限公司 | 低聚岩藻糖化糖胺聚糖及其制备方法 |
WO2011054174A1 (zh) * | 2009-11-06 | 2011-05-12 | 深圳海王药业有限公司 | 低聚岩藻糖化糖胺聚糖及其制备方法 |
US8809300B2 (en) | 2009-11-25 | 2014-08-19 | Shenzhen Neptunus Pharmaceutical Co., Ltd. | Depolymerized glycosaminoglycan from Thelenota ananas and preparation method thereof |
CN101724086B (zh) * | 2009-11-25 | 2012-09-26 | 深圳海王药业有限公司 | 低聚凤梨参糖胺聚糖及其制备方法 |
WO2011063595A1 (zh) * | 2009-11-25 | 2011-06-03 | 深圳海王药业有限公司 | 低聚凤梨参糖胺聚糖及其制备方法 |
AU2010324437B2 (en) * | 2009-11-25 | 2014-12-18 | Shenzhen Neptunus Pharmaceutical Co., Ltd. | Depolymerized glycosaminoglycan from Thelenota ananas and preparation method thereof |
CN102218076A (zh) * | 2011-04-14 | 2011-10-19 | 易杨华 | 仿刺参多糖及其在制备防治老年痴呆药物或食品中的应用 |
CN102329397A (zh) * | 2011-10-19 | 2012-01-25 | 中国科学院昆明植物研究所 | 一种岩藻糖化糖胺聚糖衍生物及其制备方法 |
CN102329397B (zh) * | 2011-10-19 | 2014-04-09 | 中国科学院昆明植物研究所 | 一种岩藻糖化糖胺聚糖衍生物及其制备方法 |
CN104147039A (zh) * | 2013-05-13 | 2014-11-19 | 上海开润生物医药有限公司 | 黑海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
WO2014183467A1 (zh) * | 2013-05-13 | 2014-11-20 | 上海开润生物医药有限公司 | 黑海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 |
CN104263788A (zh) * | 2014-09-25 | 2015-01-07 | 冯群力 | 一种海参多肽的制备方法 |
CN106137896A (zh) * | 2015-04-15 | 2016-11-23 | (株)新韩Eco | 一种利用刺参制备功能性原料的方法 |
CN106137896B (zh) * | 2015-04-15 | 2019-04-30 | (株)新韩Eco | 一种利用刺参制备功能性原料的方法 |
CN106349397A (zh) * | 2015-07-23 | 2017-01-25 | 苏州颐华生物医药技术股份有限公司 | 解聚海参糖胺聚糖组合物及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100525777C (zh) | 2009-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101057859A (zh) | 一种解聚海参糖胺聚糖组合物及其制备方法和用途 | |
CN1256080C (zh) | 果胶凝胶的就地形成 | |
JP2018154848A (ja) | 低抗凝固剤ヘパリン | |
WO2009086685A1 (zh) | 低分子量海藻酸及其盐、应用、制法及药物组合物、食品 | |
US9540454B2 (en) | High purity heparin and production method therefor | |
CA2449962A1 (en) | Use of glycosaminoglycans for the treatment of hiv-associated nephropathy | |
CN103285031B (zh) | 解聚海参糖胺聚糖在制备防治血栓栓塞疾病药物中的应用 | |
CN114846147B (zh) | 低分子量硫酸软骨素、包含其的组合物、其制备方法以及其用途 | |
EP1731131A1 (en) | Hgf production accelerator containing heparin-like oligosaccharide | |
CN1931874A (zh) | 人参糖肽的制备方法、药物制剂及医药用途 | |
US20230250199A1 (en) | Low molecular weight chondroitin sulfate, composition, preparation method and use thereof | |
CN104644591A (zh) | 一种沙格列汀药物组合物及其制备方法 | |
CN1316978C (zh) | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 | |
CN105496954B (zh) | 一种肌松药物罗库溴铵的注射液的制备方法 | |
CN104725532B (zh) | 一种精确定量控制肝素/类肝素中硫酸软骨素及硫酸皮肤素含量的方法 | |
US20220096530A1 (en) | Safe bovine heparin, preparation method, and application | |
CN1544475A (zh) | 一种古糖酯及其制备方法和应用 | |
CN105147646A (zh) | 一种苯巴比妥口腔速溶膜剂及其制备方法 | |
CN1278680C (zh) | 一种治疗出血病的药物组合及其用途 | |
CN1488399A (zh) | 尖吻蝮蛇凝血酶用作治疗出血性疾病的药物 | |
CN1473061A (zh) | 抗血栓形成的组合物 | |
CN1277554A (zh) | 葡糖胺聚糖在生产用于治疗与糖尿病有关的眼疾病的药物制剂中的用途 | |
JPH0670085B2 (ja) | コンドロイチン硫酸誘導体 | |
CN1880301A (zh) | 硫普罗宁赖氨酸及其制备方法和用途 | |
US20160082051A1 (en) | Use of sea cucumber glycosaminoglycan in preparing medicine for prevention and treatment of thromboembolic disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Xi'an Datang Pharmaceutical Group Co., Ltd. Assignor: Zhang Dengke Contract fulfillment period: 2009.9.22 to 2019.9.21 Contract record no.: 2009610000027 Denomination of invention: Depolymerization glycosaminoglycan extracted from sea cucumber composition and its preparation method and application Granted publication date: 20090812 License type: Exclusive license Record date: 20091208 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.22 TO 2019.9.21; CHANGE OF CONTRACT Name of requester: XI'AN DATANG PHARMACEUTICAL GROUP CO.,LTD. Effective date: 20091208 |
|
ASS | Succession or assignment of patent right |
Owner name: XI'AN XINTONG MEDICINE RESEARCH CO., LTD. Free format text: FORMER OWNER: ZHANG DENGKE Effective date: 20111008 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710075 XI'AN, SHAANXI PROVINCE TO: 710077 XI'AN, SHAANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111008 Address after: 710077, Xi'an hi tech Zone Kam Road Industrial Development Park No. 69, block C, 2, room 205 Patentee after: Xi'an Xintong Pharmaceutical Research Co., Ltd. Address before: 710075, No. 12, C District, 69 Kam Yip Road, hi tech Zone, Shaanxi, Xi'an Patentee before: Zhang Dengke |
|
CP03 | Change of name, title or address |
Address after: 710077 Room 205, 2nd Floor, Block C, Venture Development Park, 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Patentee after: Xi'an Xintong Pharmaceutical Research Co.,Ltd. Address before: Room 205, 2 / F, block C, venture R & D Park, 69 Jinye Road, high tech Zone, Xi'an City Patentee before: XI'AN XINTONG PHARMACY RESEARCH Co.,Ltd. |
|
CP03 | Change of name, title or address |